OverviewSuggest Edit

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The Company's nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. NanoString's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The nCounter-based Prosigna Breast Cancer Prognostic Gene Signature Assay is the first in vitro diagnostic assay to be marketed through the company's diagnostics business. The system is positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues.

TypePublic
Founded2003
HQSeattle, US
Websitenanostring.com
Employee Ratings3.6

Latest Updates

Employees (est.) (Dec 2018)476(+2%)
Job Openings24
Revenue (FY, 2018)$106.7 M(-7%)
Share Price (Nov 2019)$23.1

Key People/Management at NanoString Technologies

Brad Gray

Brad Gray

President and Chief Executive Officer
James Johnson

James Johnson

CFO
William Young

William Young

Executive Chairman of the Board
Wayne Burns

Wayne Burns

Senior Vice President, Operations & Administration
Show more

NanoString Technologies Office Locations

NanoString Technologies has offices in Seattle and Hong Kong
Seattle, US (HQ)
530 Fairview Ave N #2000
Show all (2)

NanoString Technologies Financials and Metrics

NanoString Technologies Revenue

NanoString Technologies's revenue was reported to be $106.73 m in FY, 2018
USD

Revenue (Q3, 2019)

30.6m

Net income (Q3, 2019)

(22.7m)

EBIT (Q3, 2019)

(20.7m)

Market capitalization (12-Nov-2019)

824.1m

Closing stock price (12-Nov-2019)

23.1

Cash (30-Sep-2019)

23.4m
NanoString Technologies's current market capitalization is $824.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

31.4m47.6m62.7m86.5m114.9m106.7m

Revenue growth, %

52%32%38%

Cost of goods sold

15.0m

Gross profit

16.4m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

8.4m8.8m10.9m12.3m11.6m13.1m15.7m14.7m22.6m23.9m18.1m34.6m27.0m23.1m25.0m28.6m27.7m30.3m30.6m

Cost of goods sold

3.8m4.3m

Gross profit

4.6m4.4m

Gross profit Margin, %

55%51%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

9.9m17.2m21.9m20.6m26.1m24.4m

Accounts Receivable

8.3m12.4m19.7m22.2m19.6m17.3m

Inventories

6.8m5.4m10.1m13.8m20.1m13.2m

Current Assets

60.7m95.3m82.8m113.8m121.9m131.7m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(29.3m)(50.0m)(45.6m)(47.1m)(43.6m)

Depreciation and Amortization

1.8m1.5m2.4m3.0m3.4m

Inventories

(1.4m)(1.3m)(5.4m)(5.0m)(8.7m)

Accounts Payable

1.6m21.0k(166.0k)869.0k(110.0k)
USDY, 2019

Financial Leverage

3 x
Show all financial metrics

NanoString Technologies Online and Social Media Presence

Embed Graph

NanoString Technologies News and Updates

NanoString Technologies Announces Commencement of Public Offering of Common Stock

SEATTLE, March 18, 2019 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced an underwritten public offering of 4,500,000 shares of its common stock pursuant to its shelf regi…

NanoString Technologies Provides Preliminary Operational and Financial Results for Fourth Quarter and Fiscal Year 2018

— FY18 Product and Service Revenue of $83.5 million, Exceeding High-End of Guidance —— Generated Pre-Orders for More Than 30 GeoMx™ Digital Spatial Profilers —

NanoString Technologies Releases Operating Results for Third Quarter of 2018

SEATTLE, Nov. 08, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the third quarter of 2018.

NanoString Technologies Releases Operating Results for Second Quarter of 2018

SEATTLE, Aug. 07, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the second quarter of 2018.

NanoString Technologies Blogs

A Transcriptomic Solution Customized for Your Every Need

The flexibility of the NanoString® nCounter® platform has been designed to accommodate a wide range of organisms, molecular targets, and sample inputs. Researchers can request “made-to-order” Custom CodeSets for up to 800 project-specific mRNA targets. In doing so, they can […] The post A Transcript…

The Era of Spatial Transcriptomics Falls into Place at SITC 2019

It’s that time of year again when Fall is upon us and in full swing: leaves are falling off the trees, Halloween has come and gone, pumpkin spice lattes are on every corner, and thousands of immuno-oncology researchers descend on […] The post The Era of Spatial Transcriptomics Falls into Place at SI…

Meet NanoString Scientists at the AMP 2019 Annual Meeting & Expo

When Elaine Lyon, Ph.D., a scientist on the board of the Association for Molecular Pathology (AMP) was asked why she is involved with AMP, its activities and initiatives, she quoted the famous Captain James T. Kirk from Star Trek and […] The post Meet NanoString Scientists at the AMP 2019 Annual Mee…

The challenges of profiling miRNA Biomarkers from FFPE and Clinical Biofluid Samples

In 1993, Dr. Victor Ambros’ lab discovered a small RNA sequence, Lin-4, that was “essential for the normal temporal control of diverse postembryonic developmental events in C. elegans”. Sequence analysis revealed that the molecule was 22 nucleotides long and didn’t […] The post The challenges of pro…

NanoString is headed to the Windy City for SfN!

Committed to accelerating transformative scientific discoveries, NanoString continues to develop and deliver cutting-edge molecular tools, carefully tailoring the designs to fit the specific needs of each research field and focus area. We are excited to feature our multianalyte and multiplexed […] T…

The bench side of organ transplant: Challenges and solutions

“It is infinitely better to transplant a heart than bury it to be devoured by worms,” said Dr. Christiaan Barnard, the father of the heart transplant. It’s hard to disagree with this statement! Organ transplant today is an established treatment […] The post The bench side of organ transplant: Challe…
Show more

NanoString Technologies Frequently Asked Questions

  • When was NanoString Technologies founded?

    NanoString Technologies was founded in 2003.

  • Who are NanoString Technologies key executives?

    NanoString Technologies's key executives are Brad Gray, James Johnson and William Young.

  • How many employees does NanoString Technologies have?

    NanoString Technologies has 476 employees.

  • What is NanoString Technologies revenue?

    Latest NanoString Technologies annual revenue is $106.7 m.

  • What is NanoString Technologies revenue per employee?

    Latest NanoString Technologies revenue per employee is $224.2 k.

  • Who are NanoString Technologies competitors?

    Competitors of NanoString Technologies include Varex Imaging, BG Medicine and Myriad Genetics.

  • Where is NanoString Technologies headquarters?

    NanoString Technologies headquarters is located at 530 Fairview Ave N #2000, Seattle.

  • Where are NanoString Technologies offices?

    NanoString Technologies has offices in Seattle and Hong Kong.

  • How many offices does NanoString Technologies have?

    NanoString Technologies has 2 offices.